Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Xinjing Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-2745-7262; OpenAlex author ID A5064487981. Sources: OpenAlex.

Their work

Papers
12 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 4 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 12

  1. OSBPL10-CNBP axis mediates hypoxia-induced pancreatic cancer development. Co-author DOI 10.1002/biof.2124↗
  2. Hypoxia-induced long non-coding RNA LINC00460 promotes p53 mediated proliferation and metastasis of pancreatic cancer by regulating the miR-4689/UBE2V1 axis an… First author DOI 10.7150/ijms.87833↗
  3. Aberrant human ClpP activation disturbs mitochondrial proteome homeostasis to suppress pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.chembiol.2022.07.002↗
  4. Clinical characteristics and surgical outcomes of resectable acinar cell carcinoma of the pancreas-propensity score matching analysis with pancreatic ductal ad… Co-author DOI 10.1016/j.ejso.2021.11.135↗
  5. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study. First author DOI 10.1186/s12885-022-09719-6↗
  6. Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1. First author DOI 10.1186/s13045-022-01348-7↗
  7. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914557116↗
  8. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0965-3↗
  9. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2017.04.012↗
  10. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic … First author DOI 10.1186/s12943-017-0738-0↗
  11. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma. First author DOI 10.18632/oncotarget.16732↗
  12. mir-329 restricts tumor growth by targeting grb2 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.7375↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaxing Deng · 5 shared papers, 2017–2025 · strength 0.74
  2. Xiaomei Tang · 6 shared papers, 2016–2025 · strength 0.70
  3. Xiongxiong Lu · 7 shared papers, 2016–2022 · strength 0.60
  4. Baiyong Shen · 6 shared papers, 2017–2022 · strength 0.58
  5. Chenghong Peng · 7 shared papers, 2016–2022 · strength 0.54
  6. Chenlei Wen · 6 shared papers, 2016–2022 · strength 0.47
  7. Yishu Huang · 2 shared papers, 2023–2025 · strength 0.45
  8. Ronghao Zhang · 2 shared papers, 2023–2025 · strength 0.45
  9. Xiaxing Deng · 4 shared papers, 2016–2022 · strength 0.42
  10. Weishen Wang · 3 shared papers, 2017–2023 · strength 0.39
  11. Hao Chen · 4 shared papers, 2016–2022 · strength 0.34
  12. Shuyu Zhai · 2 shared papers, 2022–2023 · strength 0.32
  13. Yuan Fang · 5 shared papers, 2016–2019 · strength 0.32
  14. Jiewei Lin · 2 shared papers, 2022 · strength 0.31
  15. Haoda Chen · 2 shared papers, 2022 · strength 0.31
  16. Qian Zhan · 3 shared papers, 2017–2022 · strength 0.28
  17. Baiyong Shen · 3 shared papers, 2016–2022 · strength 0.27
  18. Hongzhe Li · 4 shared papers, 2017–2018 · strength 0.27
  19. Zhen Huo · 4 shared papers, 2017–2018 · strength 0.27
  20. Lu Zhou · 2 shared papers, 2019–2022 · strength 0.19
  21. Ziyun Shen · 1 shared paper, 2022 · strength 0.16
  22. Da Fu · 1 shared paper, 2022 · strength 0.16
  23. Jiancheng Wang · 1 shared paper, 2022 · strength 0.16
  24. Yuanchi Weng · 1 shared paper, 2022 · strength 0.16
  25. Siyi Zou · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.